E arly reports from Mexico and Canada suggested that 2009 influenza A (H1N1; pandemic H1N1 [pH1N1]) virus infection could cause profound organ dysfunction in young adults beyond that typically seen during annual influenza epidemics (1, 2) . Early in the pandemic, 21%-48% mortality was reported for intensive care unit (ICU) patients (1, (3) (4) (5) (6) (7) , with young adults comprising the majority of fatal cases (8) (9) (10) . The major severe organ dysfunction associated with pH1N1 infection leading to adult ICU admission is rapidly progressive pneumonitis resulting in respiratory failure, acute respiratory distress syndrome, and refractory hypoxemia (11) . Postmortem findings consistently demonstrate diffuse alveolar damage with hyaline membrane formation (8, 9) . Other clinical complications include acute renal dysfunction requiring renal replacement therapy, vasopressor-dependent shock, myositis/rhabdomyolysis, encephalitis, myocarditis, and secondary invasive bacterial infection (1, (5) (6) (7) (11) (12) (13) . As in previous influenza pandemics, the frequency of bacterial infection was high, ranging from 20% to 32% of all critically ill patients (1, 6, 7) and 26% to 38% of fatal cases (8, 9) . The contribution of bacterial coinfection in the development of shock, multisystem organ failure, and death vs. pH1N1 viral infection alone remains uncertain.
Several early case series have reported on the epidemiology and general disease course of pH1N1-associated critical illness (1, 2, 7, 12, 14, 15) . Small numbers of patients, lack of reliable laboratory confirmation of cases, and narrowly focused physiologic data in these reports, however, have resulted in remaining knowledge gaps (16) . In this study, we describe the clinical features, risk factors for mortality, and outcomes of critically ill pH1N1 patients with and without bacterial coinfection admitted to acute respiratory distress syndrome network hospital ICUs across North America during the pandemic to test the hypothesis that bacterial coinfection increased the morbidity and mortality of pH1N1.
MATERIALS AND METHODS
Setting and Participants. This 1-yr multicenter observational cohort study, coordinated with a parallel study in pediatric ICUs (17), included patients 13 yrs and older with suspected, probable, or confirmed seasonal influenza or pH1N1 admitted to 35 acute respiratory distress syndrome network hospital adult ICUs from April 15, 2009 through April 15, 2010. Sites and the clinical coordinating center obtained local Institutional Review Board and waiver of consent approvals between September 22, 2009 and March 23, 2010. From the day of local Institutional Review Board approval, the records of all subsequent ICU admissions were prospectively screened for patients with influenza-like illness treated empirically with antivirals for influenza and all confirmed seasonal and pH1N1 influenza virus infections (Supplemental Fig. 1 [Supplemental Digital Content 1, http://links. lww.com/CCM/A414 ], which describes confirmed and probable pH1N1 influenza cases collected retrospectively from April 15, 2009 until the time of Institutional Review Board approval, represented by the thin blue arrow at the top. Cases were collected prospectively from the time of IRB approval through April 15, 2010, represented by the thin black arrow at the top. The red line represents the % of visits for influenza-like illness to healthcare providers as reported by the Centers for Disease Control for the duration of the study.). A confirmed case was defined as a positive test result for pH1N1 using reverse-transcriptase polymerase chain reaction (RT-PCR) or viral culture. A probable case was defined as positive diagnostic test for influenza A ( RT-PCR, viral culture, rapid diagnostic test, or immunofluorescence) that was otherwise not subtyped. Sites also retrospectively identified all confirmed and probable adult pH1N1 ICU admissions that occurred between April 15, 2009 and the date of Institutional Review Board approval.
Data Collection. Baseline demographic information, clinical presentation, and hospital course were recorded in a Web-based secure electronic case report form (REDCap) (18). Patients with human immunodeficiency virus infection, active hematologic malignancies, bone marrow or organ transplants, and those who received systemic corticosteroids at a dose of 20 mg or more of prednisone equivalent per day for any duration within 6 months of ICU admission were considered immunosuppressed. Shock was defined as being treated with vasopressors.
Date, source of sample, and result of all available influenza diagnostic tests were recorded. Baseline vital signs, vasopressor dose, Pao 2 /Fio 2 and Sao 2 /Fio 2 were the first values obtained in the ICU unless these measurements were available from transport or emergency department documentation. Data for days 3, 7, and 14 were recorded as close to 8:00 am as possible. Diagnosis of encephalitis was confirmed by magnetic resonance imaging, elevated protein in the cerebrospinal fluid, or neurology consultation. Venous thromboembolism required radiographic confirmation. Cause of death was classified by the clinicians as primary respiratory, cardiovascular, multiorgan failure, neurologic, or other.
Bacterial Coinfections. Bacterial coinfection was defined as any patient with presumed bacterial pneumonia within 72 hrs of ICU admission documented in their medical record even if cultures were negative or any patient with a positive blood culture in the first 72 hrs. In patients with presumed bacterial pneumonia, positive and negative bacterial culture results from expectorated sputum or lower respiratory tract (endotracheal or bronchoalveolar lavage) specimens were collected. Positive blood cultures in the first 72 hrs were also collected.
Statistical Analysis
Proportions were compared with chi-square testing. Continuous variables are listed as means with standard deviations or medians with interquartile ranges and compared using independent samples t testing or Wilcoxon rank sum testing. The primary analysis compared patients with bacterial coinfection to those without coinfection. Results from influenza diagnostic testing were compared according to type of test and location of specimen. RT-PCR results from lower and upper respiratory tract sources were compared if the tests were performed within 3 days of each other. SAS version 9.2 (SAS Institute, Cary, NC) was used for descriptive, bivariate, and multivariable analyses. Patients with presumed bacterial coinfection but no positive cultures from blood or respiratory secretions were excluded in a sensitivity analysis. These sensitivity analyses compared demographics, clinical characteristics, ICU course, and clinical outcomes in patients without coinfection with the subset of coinfected patients who had positive cultures (i.e., excluding those with presumed bacterial coinfection but no positive cultures from blood or respiratory secretions). Because these sensitivity analyses demonstrated no differences when patients with presumed bacterial coinfections without positive cultures were excluded, only the analyses with all 207 patients with presumed bacterial coinfection are reported. A comparison of coinfected patients with and without positive cultures is included in the appendix. Bivariate analyses used chi-square and Fisher exact tests to examine the association between baseline clinical factors and 60-day mortality. Clinical factors such as demographics, ICU admission clinical conditions, including comorbidities and coinfections, and ICU course were chosen a priori. Factors demonstrating a significant unadjusted association with 60-day mortality (p  .10) were included in subsequent multivariable analyses. The final multivariable model using SAS PROC GENMOD (19) contained all independent predictors of mortality (p  .05). Adjusted risk estimates are reported with 95% confidence limits. Kaplan-Meier curves were utilized to demonstrate survival and ventilator-dependent time.
RESULTS
Data from 683 patients with confirmed or probable pH1N1 were obtained from 35 participating hospitals. Of these, 424 (62.1%) had confirmed cases and 259 (37.9%) had probable cases. Most patients were in the ICU between September and December 2009, with almost half during October and November ( Fig. 1A ).
Demographics
Patients ranged from 13 to 92 yrs old, with a mean age of 45  16 yrs ( Fig. 1B ). Slightly less than half were male ( Table 1) . Most patients were obese, with mean body mass index of 32.5  11.1 kg/m 2 ; 52% had a body mass index  30 kg/m 2 and 32% had a body mass index  35 kg/m 2 . Comorbid conditions were present in 519 (76%) patients; diabetes and underlying lung disease were the most common (Table 1) . Immunosuppression was present in 170 (24.9%) patients with human immunodeficiency virus infection as the cause in 11% of these cases. Baseline demographics were similar between patients with and without bacterial coinfection on admission, with the exception that those with bacterial coinfection were less likely to have diabetes ( Table 1 ).
Presentation
Presenting symptoms did not differ significantly between patients with and without presumed bacterial coinfection ( Table 2) . On average, patients with and without presumed bacterial coinfection presented to the hospital (5.2  4.9 days vs. 5.0  4.5 days; p  .66) and ICU (5.8  5.3 days vs. 5.8  4.5 days; p  .94) within a similar timeframe after onset of symptoms.
On admission, the cohort had an average Acute Physiology and Chronic Health Evaluation II score of 21  9 and a Sequential Organ Failure Assessment score of 7.0  3.5. Respiratory and central nervous system dysfunction were the most prevalent (Table 1 ). Coinfected patients had higher Acute Physiology and Chronic Health Evaluation (p  .008) and Sequential Organ Failure Assessment scores (p  .001) compared to those without infection ( Table 1) .
Respiratory failure or lower respiratory tract infection was the most common reason for ICU admission. Shock was present in 90 (13.2%) patients at ICU admission, with 35 receiving high doses of vasopressors (i.e., norepinephrine 0.1 μg/kg/ min). Myositis was common on admission, with 27.5% of patients presenting with a creatine phosphokinase 500 U/L. Renal dysfunction was also seen, with 18 (2.8%) patients receiving renal replacement therapy for acute renal failure on ICU admission.
Most patients (n  486; 71.2%) had pulmonary infiltrates on chest radiographs, with an average of 2.6 quadrants involved. On the day of ICU admission, more patients with coinfections received mechanical ventilation than those without (63 vs. 52%; p  .005) and one-third of both groups received noninvasive ventilation. The mean admission Pao 2 /Fio 2 was 151  114 and the mean Sao 2 /Fio 2 was 157  124 (Table 3 ).
Influenza Diagnostic Testing
On average, 2.2  1.4 tests for influenza were recorded per patient. RT-PCR was performed most often (1.2  0.9 PCR tests/patient), followed by rapid influenza antigen testing (0.4  0.6/patient), viral culture (0.3  0.7/patient), and direct fluorescent antibody staining (0.3  0.7/patient). For confirmed cases, both rapid influenza antigen tests and direct fluorescent antibody had low sensitivity (29% and 24%, respectively) compared to RT-PCR. Fifty-two patients had RT-PCR results from both lower and respiratory tract specimens collected within a 3-day period. Fifty-five percent of the lower tract specimens were positive for pH1N1 by RT-PCR compared to 38% of upper tract specimens.
Bacterial Coinfections
Within 72 hrs of ICU admission, 207 (30.3%) pH1N1 cases had a presumed bacterial coinfection. Of these, 84 (40.6%) had bacteria identified from sputum or lower respiratory specimens, 50 (24.2%) had bacteremia, 20 (9.7%) had both positive respiratory tract cultures and bacteremia, and 53 had presumed bacterial pneumonia with negative (n  52) or no (n  1) cultures ( Table 2 ). Sensitivity analysis excluding these 53 patients with presumed bacterial coinfection but without any positive cultures demonstrated no difference in demographics (Appendix Table 1 ), clinical presentation (Appendix Table 2 ), ICU clinical course (Appendix Table 3 ), or outcomes (Appendix Table 4 ). A similar proportion of the 53 patients presumed to have bacterial coinfection but without any positive cultures presented in shock (11.2%) as the 154 with positive bacterial cultures of blood or sputum (13.6%).
Patients with presumed bacterial coinfections presented with similar temperatures, leukocyte counts, and Pao 2 / Fio 2 ratios as those without coinfections. Shock was present on admission in 21.3% of patients with compared to 10% of patients without bacterial coinfection (p  .0002). Staphylococcus aureus was the most common pathogen with bacteremia in 23 cases. Streptococcus pneumoniae was identified in 17 patients; ten had bacteremia. Four patients had group A Streptococcus in lower respiratory tract specimens on admission, with two patients also having bacteremia. Staphylococcus aureus and Pseudomonas species were the most common pathogens identified in respiratory secretions after 72 hrs from patients presenting without bacterial coinfections. Sixteen patients (6.3% of those with bacterial infections) had parapneumonic effusions or empyemas requiring drainage via thoracostomy tube or surgery.
Clinical Course
The median ICU length of stay was 5 days (interquartile range, 2-11 days; mean, 9.3  8.6 days). Patients without a bacterial coinfection had a shorter ICU length of stay (median, 6 days; interquartile range, 2-13 days; mean, 8.8  8.3 days) than coinfected patients (median, 7 days; interquartile range, 3-13 days; mean, 10.4  9.1 days; p  .05).
The majority of patients were mechanically ventilated during their ICU stay (n  478; 66%), with an average duration of 10.5 days (Fig. 2) . Mechanical ventilation was more common in patients who presented with a bacterial coinfection (74 vs. 63%; p  .008) ( Table 4 ). Two hundred thirty-one (33.8%) patients received noninvasive positive pressure ventilation, 175 (76%) of whom eventually were mechanically ventilated. More than three-fourths of patients still in the ICU on day 7 (n  355) were receiving mechanical ventilation, and 87% were still in the ICU on day 14 (n  200) ( Table 3) . Thirteen percent of patients underwent tracheostomy.
The respiratory system represented the most common and persistent organ dysfunction (Table 3 ). At least one "rescue therapy" was used in 119 (17.4%) patients, such as inhaled nitric oxide or epoprostenol (10.4%), high-frequency ventilation (8.1%), prone ventilation (5.3%), or extracorporeal membrane oxygenation (3.5%) ( Table 4 ). Of the 119, 49 (41.2%) received more than one form of rescue therapy.
Cardiovascular dysfunction was also common and prolonged, with 211 (30.9%) patients experiencing shock at some time and 20% of those in the ICU on day 3 in shock, 18% on day 7, and 21% on day 14. Patients without a bacterial coinfection had a high incidence of shock, with 17%, 20%, and 24% of those still residing in the ICU receiving vasopressors on days 3, 7, and 14, respectively. Overall, 14% of patients received new renal replacement therapy for acute renal failure. Venous thromboembolism was confirmed in 9% of patients. Seizure, myocarditis, and encephalitis were rare, occurring in 2%, 1%, and 1% of patients, respectively.
Treatment
Only 51 (7%) patients received antiviral treatment for influenza before ICU admission. Although low, a higher proportion of patients presenting after September 1, 2009, had antiviral treatment initiated before ICU admission compared with those presenting earlier in the pandemic (8.5% vs. 3.2%; p  .04). Neuraminidase inhibitors were administered to nearly all patients while in the ICU. Ninety-three percent received oseltamivir for 5 days (interquartile range, 3-7 days), with 66% and 28% receiving 75 mg and 150 mg twice daily, respectively. Approximately 4% of patients were treated with intravenous peramivir and 2% received inhaled zanamivir. Amantadine or rimantadine was used in 50 (7.3%) patients in combination with a neuraminidase inhibitor.
Survival
All-cause 28-day and 60-day hospital mortality were 21.8% and 23.4%, respectively (Table 4 ). Ten percent of deaths occurred after ICU day 28 (Fig. 2) . Sixtyday mortality was 31% in those who presented with bacterial coinfection compared to 21% in those without (p  .002). Respiratory and multiorgan failure were the most common primary causes of death, regardless of bacterial infection status, accounting for 43% and 37% of deaths, respectively. Only 5% of patients died of primary cardiovascular failure.
In multivariable analysis, age (relative risk [RR] 1.01/yr; 95% confidence interval [CI] 1.00-1.02) and immunosuppression (RR 1.57; 95% CI 1.20-2.06) were both independently associated with higher mortality (Appendix Table 1 ). Previously healthy patients experienced lower mortality (RR 0.58; 95% CI 0.38-0.89) compared to patients with comorbidities. Shock at presentation (RR 2.09; 95% CI 1.44 -3.03) and baseline oxygenation (i.e., Pao 2 /Fio 2 or Sao 2 /Fio 2 ; RR 0.99; 95% CI 0.99-1.00) were both independent predictors of mortality. Body mass index was not independently associated with mortality. Although bacterial infection was not independently associated with mortality (RR 1.43; 95% CI 0.95-2.14), coinfection with methicillin-sensitive Staphylococcus aureus at admission was independently associated with increased mortality (RR 2.82; 95% CI 1.76-4.51; p  .0001).
DISCUSSION
Critical illness with pH1N1 in this adult ICU cohort occurred predominantly in young obese adults with a high prevalence of comorbidities. The disease was typically characterized by acute hypoxemic respiratory failure from a rapidly progressive pneumonitis. Bacterial coinfection, especially with staphylococcal aureus, was associated with a significant increment in morbidity and mortality, but our findings suggest that infection with pH1N1 virus and the resulting host response can also cause severe respiratory failure, shock, and multiorgan failure without apparent bacterial coinfection. The disease progressed rapidly to critical illness in patients both with and without presumed bacterial coinfection. Few subjects received antiviral therapy before admission, suggesting a potential missed treatment opportunity.
The prevalence of bacterial coinfection, although similar to that previously reported for pH1N1 and a commonly collected pediatric cohort (8, 9, 17) , but higher than that seen in Spanish ICUs, required positive cultures (20). Bacteremia was common, occurring in 34% of those suspected of having a bacterial coinfection, most of whom had presumed pneumonia. As others have reported, Staphylococcus aureus and Streptococcus pneumoniae were the most common respiratory isolates (8, 9, 17, 20) . Coinfection on admission was associated with a higher severity of illness, increased incidence and severity of shock, and greater likelihood of requiring mechanical ventilation (20). Furthermore, in unadjusted analyses bacterial coinfection was associated with higher mortality and longer duration of mechanical ventilation (20), possibly suggesting early empirical antimicrobial treatment may improve clinical outcomes.
Substantial controversy persists over the cause of mortality during the 1918 pandemic, with recent analyses of the historical record supporting the conclusion that the virus caused a mild illness that enabled colonizing strains of bacteria to cause lethal pneumonia (21).
However, morbidity and mortality from pH1N1-associated critical illness cannot be attributed only to bacterial coinfections because 7% of patients without bacterial coinfection were in shock at presentation, with 10% on vasopressors at ICU admission, 17% were on vasopressors on ICU day 3, 63% received mechanical ventilation during their ICU stay, and 20% died before hospital discharge.
The hypoxemic respiratory failure seen with pH1N1 critical illness appeared more severe than in patients with both other influenza viruses and other etiologies of lung injury (22, 23). Patients received prolonged mechanical ventilation and nearly one in five received at least one "rescue therapy;" these rates are slightly higher than those reported in studies of patients with non-H1N1 acute respiratory distress syndrome (24). Respiratory failure was the most common cause of death, which differs from other etiologies of acute lung injury in which most patients die of multisystem organ failure (25). This observation may be explained in part by the tropism of pH1N1 virus for both the upper (i.e., tracheobronchitis) and lower airways and alveolar epithelium (8, 9) . Furthermore, the replication of pH1N1 virus is prolonged in the lower respiratory tract in critically ill patients and an exuberant local immune response in previously healthy young adults are additional possible explanations for severe lung injury (5, 8, 26) . These factors may explain why diagnostic testing of lower airway specimens result in better sensitivity and specificity than upper airway samples. Our data confirm previous reports (27-29) of low sensitivity and specificity of rapid antigen tests and direct immunofluorescence assays for pH1N1 in critically ill individuals, especially in specimens from upper airways, and confirm the need for repeat testing, preferably from bronchoalveolar lavage or other lower airway sampling technique, if initial results are negative during a pandemic.
Immunosuppression was associated with more severe illness and a 60% higher risk of mortality, an incremental risk also found in the pediatric cohort (17) and similar to receiving high-dose vasopressors on admission. Other studies have identified chronic comorbidities (congestive cardiac failure, diabetes, underlying lung disease, morbid obesity), and pregnancy as risk factors for ICU admission with pH1N1 (3, 14, (30) (31) (32) . In our cohort, none of these factors, including obesity or underlying lung disease, was independently associated with death, although similar to a previous study (6) baseline Pao 2 /Fio 2 or Sao 2 /Fio 2 levels were independently associated with mortality. Like our counterpart pediatric cohort (17), we found Staphylococcus aureus coinfection at admission, rather than pneumococcal pneumonia, as the organism associated with increased mortality (6) . However, our association was with methicillin-sensitive strains as opposed to our pediatric cohort, which found an association with methicillin-resistant Staphylococcus aureus.
Despite data from observational studies reporting less severe illness and survival benefit with early neuraminidase inhibitor treatment (3, 12, 32, 33) , only 7% of patients in this study received antivirals before ICU admission; therefore, we were unable to assess the impact of early oseltamivir treatment on outcomes. The reason for this is unknown, but possible explanations include unaccounted factors leading to delayed presentation or delay in or no antiviral treatment, failure to consider the diagnosis of pH1N1 despite an ongoing influenza pandemic, insensitive initial diagnostic tests, and rapid disease progression. Although antiviral treatment before ICU admission increased late in the pandemic, utilization remained 10%.
This study is subject to several limitations. First, similar to the pediatric cohort (17), 38% of the patients tested positive for influenza A without subtyping and were included in this cohort as having probable pH1N1 cases. It is likely that these cases were pH1N1 cases because 99% of influenza A virus strains tested during the study period were identified as pH1N1 virus (34). Second, this was a survey of clinical characteristics and practice, and we did not standardize the diagnostic approach to bacterial coinfection but rather relied on a clinical diagnosis by the treating ICU physicians, even if respiratory cultures were negative. Thus, we may have overestimated the proportion of pH1N1 virus-infected patients with bacterial coinfection. Sensitivity analysis demonstrates that patients presumed to have bacterial coinfection on ICU admission but without positive cultures were not sicker and, in fact, may have been slightly less ill, with lower severity of illness scores, less shock, and less mechanical ventilation on admission compared to the patients in the coinfection cohort with positive cultures. However, it is still possible that the sicker patients were more likely presumed to have bacterial pneumonia or were subject to more extensive testing, potentially confounding the association between bacterial coinfection and increased severity of illness and introducing potential bias in the difference in outcomes. Furthermore, most patients in this study had neither a clinical suspicion nor positive cultures for bacteria, yet they were critically ill and had multisystem organ failure. Thus, these findings support a role for pH1N1 infection per se in the genesis of a syndrome most clinicians associate with bacterial infections. In addition, administration of broad-spectrum antibiotics and the unknown sensitivity and specificity of bacterial cultures of blood and respiratory specimens for identifying the etiology of pneumonia (6) . In addition, unknown specificity of respiratory specimen culture results in identifying the etiology of pneumonia also may have resulted in an overestimation of the incidence of bacterial coinfection. Further, we did not collect time to or appropriateness of antibiotics, which also likely plays a key role in clinical outcomes. Finally, because our study was limited to patients admitted to ICUs, the associations found between coinfections and morbidity and mortality may not be generalizable to noncritically ill populations.
CONCLUSION
Although pH1N1 influenza virus caused severe respiratory and multiorgan failure and death without apparent bacterial coinfection, coinfection, especially with Staphylococcus aureus, was associated with a significant increase in morbidity and mortality among ICU patients. Despite the pH1N1 pandemic being declared over, pH1N1 virus continues to circulate worldwide, and antigenic drift is expected. Changes in viral characteristics are unpredictable, but we speculate circulating strains of pH1N1 virus will continue to cause critical and fatal multiorgan system complications, with or without invasive bacterial coinfection. Accordingly, prevention efforts, including vaccination, encouragement of symptomatic patients to seek early medical care, especially those at high-risk for influenza complications, and early neuraminidase inhibitor treatment, may help prevent progression to critical illness. Although we will never know if immunization and early and more widespread use of empirical antiviral therapy would have improved outcomes, our findings suggest that antiviral therapy should be considered for patients with comorbidities and even healthy subjects with severe symptoms during a pandemic. Initial negative influenza test results do not exclude influenza virus infection, and multiple specimens from different respiratory sites may be needed for confirmation, preferably by RT-PCR. Furthermore, for severely ill patients, empirical neuraminidase inhibitor treatment and antibiotic therapy with Staphylococcus High dose vasopressors ≥15 μg/min norepinephrine or equivalent. Days of symptoms prior to admission is reported per day.
